Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)

China flag China · Delayed Price · Currency is CNY
29.90
-1.44 (-4.59%)
Last updated: Jun 6, 2025
-14.01%
Market Cap 11.04B
Revenue (ttm) 50.24M
Net Income (ttm) -754.23M
Shares Out 366.68M
EPS (ttm) -2.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,061,601
Average Volume 4,745,167
Open 31.40
Previous Close 31.34
Day's Range 29.41 - 31.47
52-Week Range 22.11 - 36.40
Beta 1.15
RSI 57.54
Earnings Date Aug 29, 2025

About SHA:688443

Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a mo... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 743
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688443
Full Company Profile

Financial Performance

In 2024, SHA:688443's revenue was 30.09 million, an increase of 2384.11% compared to the previous year's 1.21 million. Losses were -797.27 million, -0.50% less than in 2023.

Financial Statements

News

There is no news available yet.